Call Options

9 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$5.65 - $7.76 $150,290 - $206,416
-26,600 Reduced 76.88%
8,000 $47,000
Q2 2024

Aug 14, 2024

SELL
$6.16 - $8.08 $419,496 - $550,248
-68,100 Reduced 66.31%
34,600 $239,000
Q1 2024

May 15, 2024

BUY
$7.61 - $8.63 $100,452 - $113,916
13,200 Added 14.75%
102,700 $790,000
Q4 2023

Feb 14, 2024

BUY
$5.7 - $9.14 $321,480 - $515,496
56,400 Added 170.39%
89,500 $784,000
Q3 2023

Nov 14, 2023

SELL
$6.35 - $8.16 $25,400 - $32,640
-4,000 Reduced 10.78%
33,100 $241,000
Q2 2023

Aug 14, 2023

BUY
$3.14 - $6.61 $74,104 - $155,996
23,600 Added 174.81%
37,100 $245,000
Q1 2023

May 15, 2023

SELL
$2.97 - $4.81 $5,643 - $9,139
-1,900 Reduced 12.34%
13,500 $46,000
Q4 2022

Feb 14, 2023

SELL
$2.63 - $3.45 $24,985 - $32,775
-9,500 Reduced 38.15%
15,400 $42,000
Q3 2022

Nov 14, 2022

SELL
$2.71 - $4.22 $78,590 - $122,380
-29,000 Reduced 53.8%
24,900 $71,000

Others Institutions Holding MDXG

About MIMEDX GROUP, INC.


  • Ticker MDXG
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 113,609,000
  • Market Cap $1.03B
  • Description
  • MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary pr...
More about MDXG
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.